Please assess the completion status of the following clinical trial:

Trial Title: Study of CA-008 (Vocacapsaicin) in Bunionectomy Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Healthy adult aged 18 - 75 years old~2. American Society of Anesthesiology (ASA) physical Class 1, 2 or 3~3. Planning elective Bunionectomy repair~4. For both males and females: using an acceptable method of birth control~5. If a female: not pregnant or breastfeeding~6. Have a body mass index ≤ 40 kg/m2.~7. Be willing and able to sign the informed consent form (ICF)~8. Be able to complete study procedures and pain scales and to communicate meaningfully in English~9. Be willing to undergo 17 blood draws for pharmacokinetic (PK )assessments over 24 hours~Exclusion Criteria:~1. Have another painful condition, other than bunion-related pain, that may require pain treatment during the study period~2. Have active skin disease or another abnormality at the anticipated site of surgery that could interfere with the planned surgery.~3. Have a known allergy to chili peppers, capsaicin or the components of CA-008, bupivacaine HCl, ketorolac, acetaminophen or oxycodone.~4. Have a history of significant medical, neuropsychiatric or other condition, including a clinically significant abnormal clinical laboratory test values~5. Be on any medication not allowed per the protocol~6. Within the past year have a history of illicit drug use or prescription medicine or alcohol abuse~7. Have positive results on the alcohol test (breath or saliva) or urine drug screen~8. Have previously participated in a clinical study with CA-008.~9. Have participated in another clinical trial or used an investigational product within 30 days or five half-lives (whichever is longer)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- CA-008 (vocacapsaicin) 0.7 mg (0.05 mg/mL concentration) (Type: ACTIVE_COMPARATOR): Each patient will receive a single dose of 0.7 mg CA-008 injected during an elective Bunionectomy with a multimodal analgesia regimen including a Nonsteroidal anti-inflammatory drug (NSAID) and regional Mayo block with bupivacaine.
- CA-008 (vocacapsaicin) 2.1 mg (0.15 mg/mL concentration) (Type: ACTIVE_COMPARATOR): Each patient will receive a single dose of 2.1 mg CA-008 injected during an elective Bunionectomy with a multimodal analgesia regimen including a Nonsteroidal anti-inflammatory drug (NSAID) and regional Mayo block with bupivacaine.
- CA-008 (vocacapsaicin) 4.2 mg (0.3 mg/mL concentration) (Type: ACTIVE_COMPARATOR): Each patient will receive a single dose of 4.2 mg CA-008 injected during an elective Bunionectomy with a multimodal analgesia regimen including a Nonsteroidal anti-inflammatory drug (NSAID) and regional Mayo block with bupivacaine.
- Placebo (Type: PLACEBO_COMPARATOR): Each patient will receive a single dose of CA-008 vehicle (identical to active treatment but without CA-008) injected during an elective Bunionectomy with a multimodal analgesia regimen including a Nonsteroidal anti-inflammatory drug (NSAID) and regional Mayo block with bupivacaine.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete